MedTrace Logo

Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions

NCT01908660 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 192

Last updated 2015-11-11

No results posted yet for this study

Summary

The purpose of this study is to compare the liver toxicity in HIV-infected patients with chronic hepatitis B and/or hepatitis C, who start a new antiretroviral drug regimen, as well as the influence of the degree of pre-existing liver fibrosis on the incidence of liver toxicity.

Conditions

  • Human Immunodeficiency Virus
  • Hepatitis B, Chronic
  • Hepatitis C, Chronic

Interventions

DRUG

antiretroviral drugs

zidovudine lamivudine emtricitabine abacavir tenofovir nevirapine efavirenz etravirine rilpivirine lopinavir atazanavir fosamprenavir darunavir raltegravir maraviroc ritonavir

Sponsors & Collaborators

  • Hospital Universitario Virgen de la Victoria

    collaborator OTHER

  • Hospital Universitario Reina Sofia de Cordoba

    collaborator OTHER_GOV

  • Hospital Torrecárdenas

    collaborator UNKNOWN

  • Hospital de la Línea de la Concepción

    collaborator UNKNOWN

  • Hospital Poniente

    collaborator UNKNOWN

  • Hospital Universitario Virgen Macarena

    collaborator OTHER

  • Complejo Hospitalario de Especialidades Juan Ramón Jimenez

    collaborator OTHER

  • Valme University Hospital

    lead OTHER

Principal Investigators

  • Karin I Neukam, PhD · Hospital Universitario de Valme

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2015-09-30
Completion
2015-10-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01908660 on ClinicalTrials.gov